Back to Results
First PageMeta Content
Drug discovery / Angiogenesis inhibitors / Ovarian cancer / Vascular-targeting agent / Acute myeloid leukemia / Cancer / Clinical trial / Bevacizumab / Cyclacel / Medicine / Oncology / Gynaecological cancer


To Our Stockholders: As OXiGENE’s newly appointed President and Chief Executive Officer, it is a pleasure to have the opportunity to provide you with an update on OXiGENE’s progress this year and our outlook for the
Add to Reading List

Document Date: 2014-06-11 11:57:56


Open Document

File Size: 100,13 KB

Share Result on Facebook
UPDATE